Latest period
$54.08M
YoY change
+26.2%
5Y CAGR
-20.8%
Peak year (2020)
$157.15M
Latest annual
$48.91M
Cash on Hand history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: $48.91M
Cash on Hand growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: +26.2%
Cash on Hand history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | $48.91M | +26.2% | +$10.15M | ||
| 2024 | $38.75M | -59.8% | −$57.59M | ||
| 2023 | $96.34M | +21.8% | +$17.26M | ||
| 2022 | $79.08M | -11.1% | −$9.89M | ||
| 2021 | $88.97M | -43.4% | −$68.18M | ||
| 2020 | $157.15M | +3904.8% | +$153.23M | ||
| 2019 | $3.92M | -4.6% | −$188.00K | ||
| 2018 | $4.11M | — | — |
- 2025$48.91M+26.2%
- 2024$38.75M-59.8%
- 2023$96.34M+21.8%
- 2022$79.08M-11.1%
- 2021$88.97M-43.4%
- 2020$157.15M+3904.8%
- 2019$3.92M-4.6%
- 2018$4.11M—
Cash on Hand values are taken from Spruce Biosciences's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Spruce Biosciences (SPRB)
According to Spruce Biosciences's latest reported financial statements, the company's latest reported cash and short-term investments is $54.08M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual cash and short-term investments for Spruce Biosciences (SPRB) came in at $48.91M – grew 26.2% year-over-year.
Over 2020–2025 (5 years), Spruce Biosciences cash and short-term investments expanded at a -20.8% compound annual rate, with a net decline across the window.
Spruce Biosciences cash and short-term investments peaked at $157.15M in 2020; the latest annual figure is $48.91M in 2025 (68.9% below peak).
The highest annual cash and short-term investments of $157.15M was reported in 2020. The lowest in the available history was $3.92M in 2019.
Spruce Biosciences Cash on Hand by Year
Spruce Biosciences Cash on Hand 2025: $48.91M
In 2025, Spruce Biosciences reported cash and short-term investments of $48.91M, grew 26.2% from 2024.
Spruce Biosciences Cash on Hand 2024: $38.75M
Spruce Biosciences cash and short-term investments in 2024 was $38.75M, plunged 59.8% below 2023.
Spruce Biosciences Cash on Hand 2023: $96.34M
2023's cash and short-term investments for Spruce Biosciences came in at $96.34M, grew 21.8% from 2022.
Spruce Biosciences Cash on Hand 2022: $79.08M
Spruce Biosciences posted cash and short-term investments of $79.08M in 2022, declined 11.1% below 2021.
Spruce Biosciences Cash on Hand 2021: $88.97M
Spruce Biosciences cash and short-term investments in 2021 was $88.97M.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by Cash on Hand
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation